A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Claiming Science magazine's breakthrough of the year in 2023 , these drugs are an absolute revelation: they give you ...

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

McKinsey & Company’s 2024 Future of Wellness study – which surveyed more than 5,000 consumers across the United States, Britain and China – found that 82 per cent of U.S. respondents consider wellness ...

Discover the inspiring weight loss journey of a dietitian who overcame PCOS and pregnancy challenges to achieve lasting ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

Researchers have found that polyphenols cause the secretion of hormones that may help lower a risk of developing type 2 ...